Test = U.S. Pharma Purekanachido synergy achieved major items [GNW]

Tolerated (plecanatide) Purekanachido study drug orally (CIC) is good chronic idiopathic constipation,: (SGYP NASDAQ) is the first Synergy Pharmaceuticals U.S. to develop therapeutic gastrointestinal disease - Globe Newswire] I announced today that it has achieved a key secondary endpoint, clinical trial phase 2b / 3. All test results will be presented at the meeting of this year. Also, whether to increase the number of times (CSBM) defecation voluntary full of patients Purekanachido, the company has verified straining during bowel movement or stiffness of the flight, such as the time to bowel movement first, the impact on other parameters. 951 people in the United States, the subject was conducted over 12 weeks, the placebo group were assessed capacity Purekanachido 3 (0.3,1.0,3.0 mg). <GNW>
Note: This article provides] hen Globe Newswire.